News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
中生製藥(01177.HK)：庫莫西利膠囊獲內地批准第2項適應症
中生製藥(01177.HK)公布，其附屬公司正大天晴自主開發的國家1類創新藥庫莫西利膠囊「CDK2/4/6抑制劑」(商品名：賽坦欣®)已獲得中國國家藥品監督管理局(NMPA)的上市批准，聯合氟維司群用於激素受體(HR)陽性、人表皮生長因子受體2(HER2)陰性的局部晚期或轉移性乳腺癌患者的初始內分泌治療。這是庫莫西利獲批上市的第2項適應症。(sl/w)~阿思...
Reset
Send
The window will close in 5 seconds
中生製藥(01177.HK)：庫莫西利膠囊獲內地批准第2項適應症
Close
Recommend
13
Positive
19
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

中生製藥(01177.HK)  -0.060 (-1.062%)    Short selling $71.83M; Ratio 16.178%   公布，其附屬公司正大天晴自主開發的國家1類創新藥庫莫西利膠囊「CDK2/4/6抑制劑」(商品名：賽坦欣®)已獲得中國國家藥品監督管理局(NMPA)的上市批准，聯合氟維司群用於激素受體(HR)陽性、人表皮生長因子受體2(HER2)陰性的局部晚期或轉移性乳腺癌患者的初始內分泌治療。這是庫莫西利獲批上市的第2項適應症。(sl/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-14 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.